Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. by Lewis, Michael D et al.
Lewis, MD; Fortes Francisco, A; Taylor, MC; Burrell-Saward, H;
McLatchie, AP; Miles, MA; Kelly, JM (2014) Bioluminescence imag-
ing of chronic Trypanosoma cruzi infections reveals tissue-specific par-
asite dynamics and heart disease in the absence of locally persistent
infection. Cellular microbiology, 16 (9). pp. 1285-300. ISSN 1462-
5814 DOI: 10.1111/cmi.12297
Downloaded from: http://researchonline.lshtm.ac.uk/1649020/
DOI: 10.1111/cmi.12297
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Bioluminescence imaging of chronic Trypanosoma
cruzi infections reveals tissue-specific parasite
dynamics and heart disease in the absence of locally
persistent infection
Michael D. Lewis,1* Amanda Fortes Francisco,1
Martin C. Taylor,1 Hollie Burrell-Saward,2
Alex P. McLatchie,1† Michael A. Miles1 and
John M. Kelly1
1Department of Pathogen Molecular Biology, Faculty of
Infectious and Tropical Diseases, London School of
Hygiene and Tropical Medicine, Keppel Street, London,
WC1E 7HT, UK.
2Department of Immunology and Infection, Faculty of
Infectious and Tropical Diseases, London School of
Hygiene and Tropical Medicine, Keppel Street, London,
WC1E 7HT, UK.
Summary
Chronic Trypanosoma cruzi infections lead to car-
diomyopathy in 20–30% of cases. A causal link
between cardiac infection and pathology has been
difficult to establish because of a lack of robust
methods to detect scarce, focally distributed para-
sites within tissues. We developed a highly sensi-
tive bioluminescence imaging system based on
T. cruzi expressing a novel luciferase that emits
tissue-penetrating orange-red light. This enabled
long-term serial evaluation of parasite burdens in
individual mice with an in vivo limit of detection of
significantly less than 1000 parasites. Parasite dis-
tributions during chronic infections were highly
focal and spatiotemporally dynamic, but did not
localize to the heart. End-point ex vivo biolumines-
cence imaging allowed tissue-specific quantifica-
tion of parasite loads with minimal sampling bias.
During chronic infections, the gastro-intestinal
tract, specifically the colon and stomach, was the
only site where T. cruzi infection was consistently
observed. Quantitative PCR-inferred parasite loads
correlated with ex vivo bioluminescence and con-
firmed the gut as the parasite reservoir. Chroni-
cally infected mice developed myocarditis and
cardiac fibrosis, despite the absence of locally per-
sistent parasites. These data identify the gut as a
permissive niche for long-term T. cruzi infection
and show that canonical features of Chagas
disease can occur without continual myocardium-
specific infection.
Introduction
A wide variety of pathogens establish persistent infections
by continually evading host immune-mediated clearance
and often cause chronic debilitating or fatal illnesses as a
consequence. The strategies that microbes employ to
ensure their long-term survival within mammalian hosts
include antigenic variation, establishment of sites of
latency and direct immunomodulation. The protozoan
parasite Trypanosoma cruzi is an important zoonotic
pathogen which establishes life-long infection in humans
and causes Chagas disease (American trypanosomiasis).
While the cell invasion and intracellular survival mecha-
nisms adopted by T. cruzi in acute infections are becom-
ing clearer, the adaptations that allow it to sustain chronic
infections remain poorly understood (Nagajyothi et al.,
2012).
At least 8 million people in Latin America are estimated
to be infected with T. cruzi, resulting in ∼ 13 000 deaths
annually and a significant morbidity burden (Moncayo
and Silveira, 2009). Migration patterns are also driving
globalization of the disease. For example, recent esti-
mates indicate there are 300 000 infected people living in
the USA (Bern and Montgomery, 2009) and up to 123 000
in Europe (Basile et al., 2011). Transmission is primarily
mediated by triatomine bug vectors but the congenital
route, consumption of contaminated food and drink, organ
transplantation and blood transfusion are all important
additional infection risks (Marin-Neto et al., 2008).
Clinical forms of human Chagas disease are divided
into distinct stages (Rassi et al., 2010). The acute phase
is often asymptomatic but can be severe, particularly in
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children, with death occurring in up to 5% of diagnosed
cases. Although sterile immunity is not achieved, most
infected individuals suppress parasitaemia within 4–8
weeks and enter the ‘indeterminate’ asymptomatic phase
of chronic infection. Clinical manifestations generally do
not then occur until decades later. These include chronic
chagasic cardiomyopathy (CCC) in 20–30% of those
infected, and/or digestive megasyndromes in ∼ 10% of
cases (Köberle, 1970; Arantes et al., 2004). Factors that
influence progression from asymptomatic to symptomatic
cardiac disease states are poorly understood and the
mechanism(s) of CCC pathogenesis has been con-
troversial (Gironès and Fresno, 2003; Tarleton, 2003;
Marin-Neto et al., 2007; Bonney and Engman, 2008;
Dutra and Gollob, 2008; Gutierrez et al., 2009). Damage
to the myocardium has been attributed to injury mediated
directly by the parasite, by parasite-specific inflammatory
responses, and auto-reactive immune responses. The
scarcity of parasites in histological sections from CCC
patients and the presence of auto-reactive antibodies and
T-lymphocytes in chronically infected hosts (Cunha-Neto
et al., 2011) has led many to favour autoimmune-
mediated damage to the heart as the central, or only,
pathologically relevant process (Teixeira et al., 2011).
Strong evidence now supports the continued presence of
T. cruzi in the host as a requirement for disease develop-
ment. Molecular methods have confirmed the presence of
parasite DNA and antigens in damaged tissues (Higuchi
et al., 1993; Jones et al., 1993; Añez et al., 1999), and
improved clinical outcomes have been observed in
some, but not all, trials of anti-parasitic chemotherapy
(reviewed in Marin-Neto et al., 2008). A consensus has
developed that disease pathology results mainly from pro-
inflammatory immune responses that are driven by the
continued presence of the parasite in the host. Within this
framework, however, the relative contributions of parasite-
specific and autoimmune responses to myocardial
damage remain unclear. The factors that allow T. cruzi to
continually evade immune clearance, despite a vigorous
adaptive response (Padilla et al., 2009), are also
unknown. Furthermore, the reason(s) why heart tissue is
a major site of disease pathology are not adequately
explained by existing data. Evidence for a quantitative
association between disease progression and cardiac
parasite burden during the chronic stage is equivocal,
and the cellular and molecular processes underlying
the development of myocarditis and fibrosis are poorly
defined.
Mouse models of chronic Chagas disease have fun-
damental drawbacks that have constrained their use in
studying pathogenesis. Unlike the acute phase, where
non-dividing trypomastigotes can be detected in blood
by microscopy, parasitaemia in the chronic phase is gen-
erally subpatent. In these long-term infections, most
parasites are intracellular replicative amastigotes, and
existing evidence indicates that they reside predomi-
nantly in muscle tissues (Zhang and Tarleton, 1999).
Adipocytes have been suggested as a possible second-
ary reservoir site (Matos Ferreira et al., 2011; Nagajyothi
et al., 2012). End-point assays such as histology, PCR
and serology require large animal cohorts and the utility
of such data is typically limited by tissue sampling
biases and the focal nature of tissue infections. Biolumi-
nescence imaging approaches have been developed
but have not been applied beyond the acute phase
(Hyland et al., 2008; Canavaci et al., 2010; Andriani
et al., 2011).
We have developed an enhanced in vivo imaging
system based on T. cruzi expressing a novel firefly
luciferase variant that emits tissue-penetrating orange-red
light. This enabled highly sensitive in vivo and ex vivo
imaging and long-term, serial evaluation of infections in
individual mice. This has allowed us to investigate the
association between tissue tropism and development of
chagasic heart disease with minimal tissue sampling bias.
We found that chronic infections are quantitatively and
spatially dynamic and identified the gastrointestinal tract
(GIT) as the primary site of parasite persistence. Impor-
tantly, T. cruzi-infected mice developed chronic myocardi-
tis and cardiac fibrosis, despite the absence of detectable
parasites in the heart tissue itself.
Results
Highly sensitive in vivo imaging of T. cruzi expressing
red-shifted luciferase
We previously demonstrated that the thermostable red-
shifted firefly luciferase PpyRE9h (Branchini et al., 2010)
can be used as a highly sensitive reporter for in vivo
imaging of experimental African trypanosome infections,
with dramatically improved bioluminescence detection
compared to wild-type firefly luciferase (McLatchie et al.,
2013). We therefore integrated PpyRE9h into the rDNA
locus of T. cruzi CL Brener using construct pTRIX2-RE9h
(Experimental procedures; Fig. 1A and Fig. S1). G418-
resistant parasites were screened for luciferase activity
and a highly expressing clone was selected for in vivo
experiments. When cultured as epimastigotes, this clone
grew at the same rate as wild-type parasites and differ-
entiated into metacyclic trypomastigotes that infected
L6 myoblasts normally. Staining with anti-firefly luci-
ferase polyclonal antibody showed that expression was
cytosolic, with low intra-population variation in intracellular
amastigotes (Fig. 1B). There was a linear relationship
between parasite number and luciferase activity in vitro
(103–106 cells range, R 2 = 0.999) (Fig. 1C). Luciferase
expression was similar in epimastigotes, amastigotes,
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and tissue culture trypomastigotes (Fig. 1D). Long-term
constitutive luciferase expression was preserved as
shown by activity assays performed on parasites main-
tained for > 300 days in the absence of selective drug-
pressure (Fig. 1D), using a regimen that included
passage through a severe combined immunodeficient
(SCID) mouse, inoculation into a BALB/c mouse and
recovery by ex vivo culture at 170 days post-infection
(dpi). Benznidazole treatment of in vitro infected L6
myoblasts harbouring amastigotes resulted in a dose-
dependent reduction in luciferase activity with an IC50 of
1.07 μM (Fig. 1E).
We first assessed infectivity of the bioluminescent
T. cruzi clone in SCID mice. In this model, both parental
WT and bioluminescent parasites caused acute fulminant
infections leading to humane end-points being reached
20–24 dpi. The limit of detection in vivo was estimated to
be close to 100 parasites when mice were imaged 1 h
after i.p. injection with blood trypomastigotes (BTs)
(Fig. 2A–C), similar to the level of sensitivity achievable in
mice infected with PpyRE9h-expressing Trypanosoma
brucei (McLatchie et al., 2013). With 1000 parasites and
above, there was a linear relationship between inoculum
size and whole animal bioluminescence intensity
(R 2 = 0.99) (Fig. 2B). This level of sensitivity is substan-
tially higher than seen in previous reports of biolumines-
cent T. cruzi expressing wild-type luciferase, in which
detection of parasites was restricted to acute stage infec-
tion models (Hyland et al., 2008; Canavaci et al., 2010;
Andriani et al., 2011). Quantification of whole animal bio-
luminescence following either i.p. or i.v. inoculation
showed similar inferred parasite loads that increased
exponentially over time (Fig. 2D). Treatment of SCID mice
with benznidazole (100 mg kg−1 day−1 for 5 days, starting
at 14 dpi) led to a progressive reduction of biolum-
inescence (Fig. 2E and F), reversion to subpatent
parasitaemia (Fig. 2G), and improvements in animal con-
dition, including reduced piloerection and increased
mobility. Parasites remained easily detectable by biolumi-
nescence imaging, even when peripheral blood samples
were below the detection limit for microscopic examina-
tion (Fig. 2E–G). Post-mortem histological analysis of
tissues from infected SCID mice revealed abundant intra-
cellular amastigote nests in cardiac, skeletal and smooth
muscle tissues (Fig. S2). These data clearly demon-
strated the utility of PpyRE9h-expressing T. cruzi as
a tool for real-time evaluation of acute infections in
immunocompromised mice.
Fig. 1. Generation of a T. cruzi CL Brener cell line that constitutively expresses PpyRE9h red-shifted luciferase.
A. DNA construct pTRIX2-RE9h, which targets PpyRE9h to the rDNA locus.
B. Paraformaldehyde fixed L6 rat myoblasts containing intracellular bioluminescent amastigotes stained with anti-luciferase IgG (αLuc, green)
and Hoechst 33342 DNA stain (H33342, cyan).
C. In vitro luciferase activity assay of lysates from serially diluted wild-type (WT) and transgenic ([pTRIX2-LUCRE9h]) tissue culture
trypomastigotes.
D. Luciferase activity assays of lysates of 1 × 106 wild-type (WT) and transgenic ([pTRIX2-LUCRE9h]) epimastigotes (EPI) and transgenic
amastigotes (AMA), tissue culture trypomastigotes (TCT) and TCTs after in vivo passages and ex vivo culture equating to > 300 days in the
absence of G418 drug selection (TCT+300). Data are means + SEM of three to four biological replicates.
E. Luciferase activity assay of lysates from L6 rat myoblast monolayers infected with bioluminescent amastigotes and treated with increasing
concentrations of benznidazole; data are mean ± SD of triplicate wells.
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Fig. 2. Evaluation of T. cruzi infection in SCID mice by in vivo bioluminescence imaging.
A and B. Evaluation of in vivo limit of parasite detection.
A. Representative ventral images of SCID mice 1 h after i.p. injection with 1 × 100-1 × 105 blood trypomastigotes (BTs) of PpyRE9h
luciferase-expressing T. cruzi. Pseudocolour heat-maps indicate intensity of bioluminescence from low (blue) to high (red). All images use the
same log10 scale heat-map, minimum and maximum radiance values as indicated. Red circles indicate regions of interest (ROI) used for
signal quantification.
B. Quantification of abdominal bioluminescence for mice in the experiment illustrated in A.
C. Abdominal bioluminescence for mice 1 h after i.p. injection with 0, 100 or 1000 BTs (means ± SD, circles indicate values for individual
animals, n = 5 per group). P-values shown are for one-way ANOVA comparisons between infected groups and the uninfected control group.
D. Whole animal total ventral bioluminescence for SCID mice inoculated via i.p and i.v. routes (data are means ± SD, n = 3 per group).
E. Example ventral view images of the same individual SCID mouse 7, 14, 18 and 19 days after i.p. injection with 1 × 103 BTs (upper panels)
and comparison with an equivalent infected mouse treated with 100 mg kg−1 day−1 benznidazole (BZ) for 5 days starting at 14 dpi (lower
panels). All images use the same log10 scale heat-map with minimum and maximum radiance values as indicated.
F. Whole animal total ventral bioluminescence for mice in the experiment represented in E (data are means ± SD, n = 3 per group, one
experiment). BZ, benznidazole treated; NT, not treated.
G. Microscopy-based quantification of peripheral parasitaemia for animals in the experiment represented in E (means ± SD, n = 3 per group);
limit of detection = 2 × 104 ml−1. #, NT below detection limit; ##, BZ below detection limit.
B, D and F. Grey lines indicate detection thresholds determined as the mean (solid line) and mean +2SDs (dashed line) of background
luminescence of control uninfected mice using abdominal (B) or whole animal (D, F) ROI.
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Chronic T. cruzi infections are highly dynamic
As in humans, chronic infections in mice are character-
ized by microscopically subpatent parasitaemia. Further-
more, techniques that allow parasite burden and
distribution to be monitored in real-time over the course of
long-term infections have not been reported. The high
sensitivity of our bioluminescent reporter parasite system
suggested it would allow us to track such infections in
individual immunocompetent animals. We found that the
bioluminescence profile in i.p. infected BALB/c mice ini-
tially followed a pattern similar to that observed in SCID
mice, with restriction to the abdomen, followed by rapid
dissemination (Fig. 3A). The bioluminescence-inferred
parasite burden peaked at 14 dpi and then reduced pro-
gressively until stabilizing between 28 and 42 days after
infection, reflecting the transition from the acute to the
chronic phase. Bioluminescence in individual mice then
fluctuated throughout the course of the infection, at a level
100- to 1000-fold lower than the acute phase peak
(Fig. 3A–C). Peripheral blood parasitaemia was detect-
able only at the peak of acute infection (14 dpi), with a
maximum of 2.4 × 105 trypomastigotes ml−1 (not shown).
The courses of infection in mice inoculated with BTs via
the i.p., i.v. or s.c. routes did not vary significantly (Fig. 3B
and C). Compared with BT inoculations, tissue culture
trypomastigotes (TCTs) or metacyclic trypomastigotes
(MTs) generated 2.3-fold and 1.5-fold lower acute biolu-
minescence peaks at 14 dpi respectively but led to similar
chronic infection profiles (Fig. 3C).
After resolution of the acute phase, bioluminescence
was typically restricted to between one and five discrete
foci per animal, the spatial distribution of which was
highly variable (Fig. 3A and D and Fig. S3). Sites fre-
quently associated with bioluminescent foci, included the
abdomen, mouth/snout, and positions consistent with a
variety of lymph nodes, e.g. cervical, inguinal, axial and
mastoid sites. Bioluminescence associated with the posi-
tion of the heart was rarely observed. In parallel to the
frequent fluctuations in whole body bioluminescence, the
magnitude of signal from individual foci was also highly
dynamic between time points, with foci appearing and
disappearing over the course of a single day; few foci
were detectable for more than 24 h (Fig. 3D and E and
Fig. S3). The same spatially and quantitatively dynamic
distribution of bioluminescence during chronic infection
was observed irrespective of inoculation route (i.p., i.v. or
s.c.) or infective form (BT, TCT or MT). Since the CL
Brener strain amastigote doubling time is 16–20 h and
the intracellular cycle is 6–8 days, this spatio-temporal
pattern is unlikely to reflect parasites replicating in situ
within distinct tissues sites. Rather, the data suggest that
a large proportion of the chronic parasite burden detect-
able by whole animal bioluminescence imaging is likely to
be due to infected host cells being trafficked around the
body. Given the capacity of this system to detect as few
as 100 parasites dispersed within the peritoneal space
(Fig. 2C), the distinct bioluminescent foci observed in the
chronic phase (Fig. 3A and D and Fig. S3) may well cor-
respond to single infected cells, which can contain up
to 500 amastigotes and would act as a point source of
bioluminescence.
The gut is the primary site of parasite persistence in the
BALB/c model of chronic Chagas disease
To investigate T. cruzi tissue tropism in the absence of
adaptive immunity, ex vivo bioluminescence imaging
was conducted on different organs and tissue samples
from SCID mice with fulminant acute infections. All tissue
types obtained from these mice were found to display
detectable bioluminescence (Fig. S2). Quantification of
tissue/organ-specific radiance, which is a measure of bio-
luminescence per unit of surface area, showed that in this
immunodeficient host, the highest inferred relative para-
site loads were present in visceral fat deposits, the uterus,
ovaries, gut mesenteries, and the spleen (Fig. S2). The
high relative abundance of parasites in these tissues com-
pared to other sites occurred in both i.p and i.v. inoculated
SCID mice (Fig. S2).
To identify sites of T. cruzi persistence in a chronically
infected immunocompetent host, ex vivo imaging was
conducted at different stages of infection in BALB/c mice.
This revealed large spatiotemporal changes in tissue-
specific parasite burdens over time, not all of which had
been evident from whole animal imaging (Figs 3A and D
and 4A and B, Figs S3 and S4). At the peak of acute
infection (14 dpi), parasite bioluminescence was detect-
able in all tissues examined, with the highest parasite
loads associated with visceral and subcutaneous adipose
deposits (Figs 4A and 5A and Fig. S4). Around the acute-
chronic transition (35 dpi), the average parasite burden
had decreased dramatically in most tissues (Figs 4A and
5A and Fig. S4). In pilot experiments, ex vivo imaging
analyses of chronically infected mice showed that biolu-
minescence was not detectable in most organs. There-
fore, to minimize necropsy time and so maximize parasite
detection sensitivity, we chose to focus on a subset of
tissues, including those most relevant to human Chagas
disease, namely the heart and GIT, as well as other can-
didate reservoir sites including skeletal muscle and
adipose tissue. At chronic infection time points (84 and
153–161 dpi), the parasite burden was almost completely
restricted to the GIT, specifically the colon and the
stomach, with minor bioluminescence signals associated
with the skeletal muscle or gut mesenteries in some
animals (Figs 4B and 5A). We considered that our use of
i.p. injection to inoculate parasites might represent a
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Fig. 3. Chronic T. cruzi infection is highly dynamic in space and time.
A. Representative ventral view images of the same BALB/c mouse taken at sequential time points over the course of 140 days after i.p.
inoculation with 1 × 103 PpyRE9h luciferase-expressing T. cruzi CL Brener blood trypomastigotes (BT) (representative of n = 3–6 per
experiment). Heat-maps are on log10 scales and indicate intensity of bioluminescence from low (blue) to high (red); the minimum and
maximum radiances for the pseudocolour scale are indicated.
B. Quantification of whole animal total ventral bioluminescence for three individual mice from the experiment represented by the images in A.
Grey lines indicate detection thresholds determined as the mean (solid line) and mean +2SD (dashed line) of background luminescence of
control uninfected mice.
C. Quantification of whole animal total ventral bioluminescence of mice inoculated with 1 × 103 BTs, tissue culture trypomastigotes (TCT) or
metacyclic trypomastigotes (MT) via i.p., i.v. or s.c. routes. Data are shown for three individual mice per group. Grey lines indicate detection
threshold limits determined as in B.
D. Paired ventral and dorsal view images of the same individual chronically infected mouse imaged at increased frequency over a 48 h period
starting on day 125 pi (representative three mice per experiment). Heat-maps are on log10 scales and indicate intensity of bioluminescence
from low (blue) to high (red); the minimum and maximum radiances for the pseudocolour scale are indicated.
E. Quantification of total ventral (V) and dorsal (D) bioluminescence for three individual animals represented by images in D. Grey lines
indicate detection threshold limits determined as in B.
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confounding factor affecting tissue distribution of T. cruzi,
even after several months. However, ex vivo analysis of
tissues from mice 156–163 days after subcutaneous
inoculation also demonstrated that bioluminescence was
consistently detected in the GIT and in no other tissue
(Figs 4B and 5A).
To validate bioluminescence as an accurate proxy for
parasite burden, we used tissue-specific qPCR to quantify
T. cruzi DNA (190 bp satellite locus) in tissue samples
from infected mice that had been analysed by ex vivo
imaging. Targeting this locus, present at ∼ 10 000 copies
per cell, can permit detection of a single parasite in 1 ml of
Fig. 4. Tissue-specific ex vivo imaging
identifies the gut as the primary site of
T. cruzi persistence.
A and B. Representative ex vivo
bioluminescence images for selected organs
and tissues taken from BALB/c mice at
different times after infection with 1 × 103
PpyRE9h luciferase-expressing T. cruzi CL
Brener parasites. Animals were perfused with
0.3 mg ml−1 d-luciferin in PBS via the heart
immediately post-mortem, then samples were
excised and incubated in 0.3 mg ml−1
d-luciferin in PBS during bioluminescence
evaluation in an in vivo imaging platform.
Heat-maps are on log10 scales and indicate
intensity of bioluminescence from low (blue)
to high (red); the minimum and maximum
radiances for the pseudocolour scale are
indicated. Yellow (uninfected control and 35,
84, 159 and 161 dpi) or black (14 dpi) lines
demarcate regions of interest used to quantify
tissue-specific bioluminescence. C, colon;
H, heart; L, lung; GM, gut mesenteries;
SM, skeletal muscle; Sp, spleen; St, stomach;
VF, visceral fat.
A. Representative images for ex vivo analysis
at 14, 35 and 84 days after i.p. inoculation
and for uninfected control. Note the high
bioluminescence signals at 14 dpi generate
detectable reflection at the Petri dish edge but
not at later time points.
B. Representative images for ex vivo analysis
at 159–161 days after i.p. inoculation,159
days after s.c. inoculation and for uninfected
control.
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blood (Piron et al., 2007). There was a clear correlation
between qPCR-inferred and bioluminescence-inferred
parasite loads (Fig. 5B). Importantly, comparison of
tissue-specific qPCR-inferred parasite loads confirmed
the observations made with bioluminescence, including
the key findings that in chronic infections, the GIT was the
main site of persistence and parasites could not be
detected in the heart (Fig. 5C). Indeed, extrapolating from
the qPCR data at 84 and 153–161 dpi, we estimated that
there was less than 1 parasite equivalent per 106 heart
cells, indicating that this organ is essentially parasite-free
in this infection model. Taken together these data clearly
show that the GIT, the colon and stomach in particular,
represents the primary site for long-term parasite persis-
tence in immunocompetent BALB/c mice infected with the
CL Brener T. cruzi strain.
Development of chronic phase cardiac pathology in the
absence of detectable parasite load
We next aimed to address the question of whether
chronically infected mice displayed chagasic heart
disease pathology in the absence of detectable, locally
persistent T. cruzi infection. Cardiac muscle in infected
BALB/c mice consistently displayed significant levels of
diffuse inflammatory mononuclear cell infiltration (Fig. 6A
and B), as well as mild oedema throughout the course of
infection. Significant deposition of collagen in heart
tissue sections indicated the development of fibrosis in
chronic infections (Fig. 6C and D). BALB/c skeletal
muscle sections displayed evidence of inflammation and
interstitial oedema at all the time points, although this
was only significant at 35 dpi (P < 0.0001) (Fig. 6E and
F). However, in contrast to cardiac muscle, skeletal
muscle showed no evidence of fibrosis (not shown).
Parasites were not observed in histological sections of
heart, skeletal muscle or GIT samples from infected
BALB/c mice at any time point. Thus, T. cruzi infected
BALB/c mice displayed chronic myocarditis and cardiac
Fig. 5. Quantification of tissue-specific parasite loads in
T. cruzi-infected BALB/c mice.
A and B. Quantification of ex vivo bioluminescence for selected
organs and tissues taken immediately post-mortem from BALB/c
mice infected with PpyRE9h luciferase-expressing T. cruzi.
A. Animals were inoculated by i.p. injection of 1 × 103
trypomastigotes and ex vivo imaging was performed at 14 dpi
(n = 8), 35 dpi (n = 9), 84 dpi (n = 9) and 153–161 dpi (n = 8). Ex
vivo imaging was also performed at 156–163 dpi on mice that had
been inoculated by s.c. injection of 1 × 103 trypomastigotes (n = 6).
Data are means + SEM of the fold-change in bioluminescence
intensity for organs from infected mice compared with matching
organs from uninfected mice and are pooled from two independent
experiments (n ≥ 3 mice per time point per experiment). Dashed
line indicates the detection threshold equal to the mean +2SDs of
the fold-change in bioluminescence intensity for empty regions of
interest (ROI) in the images obtained for 153–160 dpi (ip) infected
mice compared with empty ROI in the images obtained for
uninfected mice.
B. Correlation between ex vivo bioluminescence-inferred and
qPCR-inferred parasite loads in individual tissues samples (n = 70
samples from 20 mice from four independent experiments).
C. qPCR analysis of tissue-specific parasite burdens in mice
inoculated i.p and sacrificed 14, 35, 84 and 153–161 dpi (n = 3–4
per group, one experiment). DNA was extracted from tissue
samples and the relative amounts of T. cruzi DNA and murine DNA
were quantified by real-time PCR amplification of a parasite locus
(195 bp satellite) and a mouse control gene (gapdh). #, 84 dpi
below detection limit; ##, 153–161 dpi below detection limit;
###, 84 dpi not done.
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fibrosis, which are hallmarks of chagasic heart disease,
despite the absence of parasites in the heart as meas-
ured by histology, bioluminescence imaging or highly
sensitive tissue-specific qPCR.
Discussion
One of the major goals of Chagas disease research has
been to gain a better understanding of infection dynamics
during chronic stage infections, and their association with
the development of pathological outcomes. Progress in
this area has been limited because of the scarcity of
T. cruzi in blood and the difficulty of sampling tissue para-
sites with existing detection methods. Employing a new,
highly sensitive bioluminescence imaging model, we were
able to track the course of T. cruzi infection in individual
BALB/c mice for many months and quantify tissue-
specific parasite burdens at different stages of infection
through post-mortem ex vivo imaging. The CL Brener
clone used in this study has been considered ‘myotropic’,
because parasites have consistently been observed in
heart and muscle tissues during the acute phase of infec-
tion (Melo and Brener, 1978; Waghabi et al., 2002; Roffê
et al., 2006; Rodrigues et al., 2010). However, compre-
hensive histological analysis has demonstrated ubiqui-
tous tissue distribution in CL Brener acute infections, with
highest parasite loads in adipose tissue (Lenzi et al.,
1996). Our data corroborated this widespread tissue
distribution of parasites during the acute phase in
immunocompromised and immunocompetent models and
indicated that tissues with high adipose content har-
boured the highest parasite loads (Figs 4A and 5A, and
Fig. S4). The tissue distribution of T. cruzi during the
chronic stage was strikingly different. We found that reso-
lution of acute infections involves efficient parasite clear-
ance from most tissue types, including the heart and
adipose, resulting in long-term persistent infections char-
acterized by a highly restricted distribution of parasites.
Ex vivo imaging showed that the GIT is the only site that
consistently acts as a parasite reservoir in this murine
model. In particular, the colon and/or the stomach were
always associated with bioluminescent foci. Chronic
phase ex vivo GIT bioluminescence was typically highly
focal, but displayed relatively low variation in intensity
between mice, indicating a numerically stable but spatially
dynamic parasite load in this organ.
Data on the presence of T. cruzi in the gut in humans is
limited. Histological investigations have identified persis-
tence of parasites in GIT samples in 20–50% of mega-
oesophagus cases (Adad et al., 1991; de Castro Côbo
et al., 2012), but using PCR-based strategies other
authors have found T. cruzi DNA in 100% of such samples
(da Silveira et al., 2005). Nevertheless, anti-parasitic
chemotherapy has not been previously considered justifi-
able for seropositive individuals with digestive symptoms,
but normal heart function (Bern, 2011). This is primarily
due to a lack of evidence for the efficacy of treatment in
improving the outcome of digestive forms of chronic
Chagas disease, but is also influenced by the prevailing
view that megasyndromes are the result of denervation of
the GIT during the acute phase of infection (Köberle,
1970; de Oliveira et al., 1998). Under this hypothesis,
initial denervation in the gut is caused by iNOS-mediated
collateral destruction during acute inflammatory re-
sponses to local infection (Arantes et al., 2004). Further
age-related denervation is thought to gradually unmask
the parasite-driven losses, leading to progressive organ
dilatation and dysfunction. Our finding of long-term per-
sistence of T. cruzi in the GIT raises the possibility
that local infection may continue to influence the develop-
ment of digestive forms of Chagas disease into the
chronic phase. An intriguing question is the extent to
which gut-resident parasites may also influence disease
pathogenesis at distant sites, such as the heart. The bio-
luminescence imaging model used in this study will be a
valuable tool for investigating this and other questions
relating to the significance of T. cruzi sequestration in
the gut.
A second feature of T. cruzi infection is our observation
of large quantitative variations in whole animal biolumi-
nescence, coupled with highly dynamic spatial variation of
bioluminescence foci, both occurring at a frequency of
less than 24 h (Fig. 3 and Fig. S3). Interpretation of this
finding is complicated by the fact that the detection thresh-
old is dependent on the three-dimensional position of
parasitized cells. The same number of parasites will gen-
erate a stronger signal from peripheral sites than from
within deep tissue. This could explain why abdominal foci
were transient by in vivo imaging (Fig. 3 and Fig. S3),
while the ex vivo data always demonstrated chronic infec-
tion in the gut (Figs 4 and 5). Anatomical movement of the
GIT might explain some slight spatial fluctuations in the
abdominal region, but we also observed dynamic foci in
the thoracic area and regions of the head. In some cases,
the rapid appearance and disappearance of biolumines-
cent foci may derive from visualization of mature
pseudocysts prior to rupture in sites where only the final
stages of the intracellular cycle of amastigote multiplica-
tion are above the detection threshold. The most parsi-
monious interpretation, however, is that during chronic
infection, mobile host cells harbouring parasites, presum-
ably phagocytes, continually traffic to and from peripheral
sites. Such movement of infected cells between sites that
have different detection thresholds, combined with varia-
tion in the parasite load of individual cells would explain
the spatiotemporal dynamism in the data. This hypothesis
is further supported by the frequent association of biolu-
minescence foci with the anatomical positions of lymph
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nodes and our subsequent ability, when informed by
bioluminescence, to derive parasite cultures from these
nodes. The data presented indicate that parasites do
traffic to sites outside the GIT but are unable to maintain
long-term foci of infection outside this site. Such continual
but transient migration to peripheral sites may represent
an adaptation that facilitates uptake by haematophagous
triatomine vectors. This process may also have a role in
the association between immunosuppression and the
development of rare forms of Chagas disease such as
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meningoencephalitis (Ferreira et al., 1997) and cutane-
ous plaques (Riganti et al., 2012).
Restriction of T. cruzi to the GIT and transient escape to
other sites implies a model of long-term parasite persis-
tence where the mammalian host is able to mount effec-
tive systemic anti-parasite responses, but that T. cruzi is
able to evade these within the gut niche. This is analagous
to the strategy employed by Leishmania major, which
establishes chronic asymptomatic infection in the skin
after resolution of acute cutaneous lesions, a process
mediated by IL-10 and regulatory T cells (Belkaid et al.,
2001; 2002; Anderson et al., 2007). Like the skin, the
immunological microenvironment of the mammalian gut is
generally anti-inflammatory and tolerogenic due to the
constitutive presence of commensal microbes and food
antigens against which inflammatory responses would be
counter-productive (Macpherson and Smith, 2006; Murai
et al., 2009). Features of the gut microenvironment,
including high levels of IL-10, abundant regulatory T cells
and macrophage populations that are refractory to activa-
tion (Smythies et al., 2005) may therefore create a per-
missive niche for long-term T. cruzi persistence. It is also
likely that the parasite can actively modulate host cell
phenotypes to its long-term benefit, for example, via mul-
tiple enzymatic antioxidant strategies (Piacenza et al.,
2009) or inhibition of antigen presentation (La Flamme
et al., 1997).
Variation in Chagas disease presentation, progression
and differential organ involvement is assumed to be influ-
enced by both host and parasite factors (Dutra and
Gollob, 2008), yet very few candidate mechanisms have
been identified. There is a consensus that development
and progression of CCC is dependent on the continuous
presence of T. cruzi in the infected host and that chronic
inflammation in the heart is the primary feature that drives
tissue damage (Marin-Neto et al., 2007; Gutierrez et al.,
2009). The proposed association between persistence of
parasites in the heart and development of cardiomyopa-
thy is based on the detection of T. cruzi antigens and
genomic material in chagasic hearts from humans
(Higuchi et al., 1993; Jones et al., 1993; Añez et al., 1999)
and experimentally infected animals (Zhang and Tarleton,
1999). However, a quantitative correlation between
ongoing cardiac parasite burden and disease progression
has yet to be established. An intensive histopathological
analysis of human chagasic hearts failed to find a corre-
lation between antigen levels and markers of disease
severity (Palomino et al., 2000). The severity of CCC
in C57BL/6 mice infected with the T. cruzi Colombian
strain, as determined by serum creatine kinase cardiac
isoenzyme MB activity and electocardiograph abnormali-
ties, was also found not to have any association with local
parasite burden or myocarditis intensity (Silverio et al.,
2012). The fact that anti-trypanosomal chemotherapy may
improve disease outcome does support the requirement
of parasite persistence for pathology, but it cannot give
insight into organ-specific effects. Lastly, nucleic acid and
antigen detection methods do not demonstrate the pres-
ence of live parasites – a limitation that can be addressed
by the use of bioluminescent reporter parasites, as in this
study. Our data challenge the idea that chronic parasitism
of the myocardium itself directly sustains pathogenic myo-
carditis. Heart-specific bioluminescence was not detected
in chronic stage infections, yet we observed myocarditis
and diffuse fibrosis, which are hallmarks of CCC in
humans. Although we cannot completely exclude the pos-
sibility of transient cardiac parasitism, this was not detect-
able by in vivo or ex vivo imaging, tissue-specific qPCR,
or histological analysis. The finding of an apparent inverse
correlation between parasite burden and accumulation
of fibrosis in the heart could be due to tissue damage
linked to immune-mediated clearance of local parasites.
Fig. 6. Histological evidence for chronic cardiac inflammation and fibrosis in T. cruzi infected BALB/c mice. Cardiac and skeletal muscle
samples were obtained at acute and chronic stages of infection after inoculation with 1 × 103 trypomastigotes via i.p. [14 (n = 8), 35 (n = 9), 84
(n = 9) and 153–161 (n = 8) dpi] or s.c. [156–163 dpi only (n = 6)] injection and from uninfected control mice (n = 8) from the same cohorts as
the 153–163 dpi animals, then processed for histopathological analysis.
A. Quantitative analysis of myocarditis. The level of cellular infiltration into cardiac muscle was assessed by automated counting of the number
of nuclei in haematoxylin-eosin stained cardiac muscle sections from T. cruzi infected and uninfected control mice to derive an inflammation
index (nuclei per 6 × 104 μm2).
B. Representative images of cardiac muscle from mice at different stages of infection compared with uninfected controls (haematoxylin-eosin
stain).
C. Quantitative analysis of cardiac fibrosis. The level of fibrosis in cardiac muscle was assessed by automated counting of the area of
collagen (blue) in cardiac muscle sections stained with Masson’s trichrome from T. cruzi infected and uninfected control mice to derive a
fibrosis index (collagen per μm2).
D. Representative images of cardiac muscle from mice at different stages of infection compared with uninfected controls (Masson’s trichrome
stain).
E. Quantitative analysis of skeletal muscle inflammation. The level of cellular infiltration into skeletal muscle was assessed as for cardiac
muscle.
F. Representative images of skeletal muscle from mice at different stages of infection compared with uninfected controls (haematoxylin-eosin
stain).
A, C and E. Data are the means + SEM of six to nine mice per time point pooled from two independent experiments (n ≥ 3 mice per time point
per experiment); circles indicate values for individual animals. Asterisks indicate P-values for one-way ANOVA (A, E) or Kruskal–Wallis (C)
comparisons between infected groups and uninfected control groups (*P < 0.05; **P < 0.01; ***P < 0.001).
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However, several aspects of the data are inconsistent with
such an interpretation. Inflammation was observed in
skeletal muscle but fibrosis did not develop, despite
longer-lasting persistence of parasites in this tissue. The
intensity of cardiac inflammation was elevated throughout
the infection and so did not correlate with heart-specific
parasite load and, crucially, continued in hearts that were
free of detectable parasites. Moreover, the relative reduc-
tion in heart-specific parasite load between 84 dpi and
153 dpi was negligible compared to the decrease
between 14 dpi and 84 dpi, yet these periods were asso-
ciated with approximately equal levels of collagen depo-
sition. Our data are therefore more consistent with a
model of CCC development in which the pathologically
relevant inflammation of the cardiac muscle is not
dependent on parasites residing continuously in the myo-
cardium. This does not imply that autoimmunity is the sole
explanation for ongoing damage to the heart. As men-
tioned above, we cannot exclude transient, but important
episodes of direct cardiac tissue infection or infiltration
into the heart by antigen presenting cells infected with
T. cruzi. Indeed, a recent study has shown that heart-
specific parasite burdens in a fatal acute infection model
were critically dependent on the ability of T. cruzi to rep-
licate in myeloid cells, and not on systemic parasitaemia
(Calderón et al., 2012), suggesting these cells were traf-
ficking parasites into the heart. This hypothesis fits with
our observation of spatiotemporally dynamic foci during
the chronic phase of infection. It will therefore be interest-
ing to determine whether such ‘Trojan horse’ models can
help to explain parasite dynamics and pathogenesis in
chronic infections.
Trypanosoma cruzi is a highly diverse species com-
prised of four major genetic lineages and two inter-lineage
hybrid groups (Lewis et al., 2011). The severity of heart
disease in experimental models is known to vary between
different combinations of parasite and mouse strain
(Postan et al., 1987; Andrade and Magalhães, 1997;
Marinho et al., 2004; Roffê et al., 2012). As demonstrated
in this study, bioluminescence imaging technology now
has the potential to generate a fuller understanding of
long-term infection dynamics for other T. cruzi strains and
their association with Chagas disease pathogenesis.
More broadly, the use of red-shifted luciferase reporters
has clear potential to improve in vivo imaging models
where detection sensitivity is a limiting factor.
Experimental procedures
Parasites
The T. cruzi strain CL Brener (genotype TcVI), was cultivated as
epimastigotes in supplemented RPMI-1640 medium at 28°C
as described previously (Kendall et al., 1990). Metacyclic
trypomastigotes (MTs) were obtained by transferring exponen-
tially growing epimastigotes to transformation medium (Graces-
IH) at 4 × 106 parasites ml−1 (Isola et al., 1986). MTs were
harvested after 4–7 days, when typically 70–90% of parasites
had differentiated. Tissue culture trypomastigotes (TCTs) were
obtained from infected L6 rat skeletal myoblasts grown in sup-
plemented RPMI-1640 medium at 37°C and 5% CO2.
Vector construction and transfection
The rRNA promoter sequence in plasmid pTRIX (Bot et al., 2010)
was modified to introduce a 5′ AatII site generating pTRIX2. The
firefly luciferase gene variant PpyRE9h (Branchini et al., 2010)
was amplified from the plasmid pTb-AMluc-v (McLatchie et al.,
2013) using primers 5′-GTTTGGATCCATGGAGGACGCCAA
GAACATC-3′ and 5′-GTTTCTCGAGTCAGATCTTGCCGCCC
TTCT-3′. It was then cloned into pGEM-T Easy vector, excised
using BamHI and XhoI (sites underlined) and then inserted into
the multiple cloning site of pTRIX2 to produce the plasmid
pTRIX2-RE9h. For transfections, 10 μg of pTRIX2-RE9h was
digested with AatII and AscI and the 5.85 kb fragment was
gel purified (Fig. 1A). A total of 1 × 108 epimastigotes were
electroporated with the Amaxa Nucleofector II, using program
X-001 and human T-cell nucleofector buffer (Lonza). Transgenic
clones with were obtained by selection with 120 μg ml−1 G418.
Genomic integration was confirmed by Southern blotting.
In vitro assays
The Luciferase Assay System (Promega) was used to assess
luciferase expression in G418-resistant clones from in vitro cul-
tures. Briefly, 5 × 106 parasites were washed in PBS then lysed in
CCLR buffer at 1 × 106 parasites ml−1. Ten microlitres of lysate
was mixed with 90 μl of substrate and luminescence was meas-
ured immediately using a SpectraMax® M3 microplate reader
(Molecular Devices). To assess luciferase expression in indi-
vidual amastigotes, L6 myoblasts grown on glass coverslips were
processed for immunofluorescence analysis 5 days after infec-
tion. Coverslips were fixed in 2% paraformaldehyde in PBS,
permeabilized using 0.1% Triton X-100, then stained with 1:500
goat anti-luciferase pAb (Promega) followed by 1:1000 Alexa488
conjugated donkey anti-goat IgG (Invitrogen). DNA was labelled
using 1 μM Hoechst 33342 before mounting with FluorPreserve
(Calbiochem). Images were acquired on an LSM 510 confocal
microscope (Zeiss).
Mice and infections
All animal work was carried out under UK Home Office project
licence (PPL 70/6997) and was approved by the London School
of Hygiene and Tropical Medicine Ethics Committee. All protocols
and procedures were conducted in accordance with the UK
Animals (Scientific Procedures) Act 1986 (ASPA). BALB/c mice
were purchased from Charles River (UK) and CB17 SCID mice
were bred in-house. Animals were maintained under specific
pathogen-free conditions in individually ventilated cages. They
experienced a 12 h light/dark cycle and had access to food and
water ad libitum. Female mice aged 8–12 weeks were used in all
experiments. In standard experiments, 1 × 104 in vitro derived
TCTs in 0.2 ml PBS were first used to infect SCID mice via i.p.
inoculation. Peripheral blood parasitaemias were determined by
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diluting 3 μl blood in 27 μl red blood cell lysis buffer and counting
using a haemocytometer. Blood from SCID mice was then
adjusted to 5 × 103 BTs ml−1 with PBS. BALB/c mice were
infected with 1 × 103 BTs via i.p injection. In some experiments,
mice were infected with up to 1 × 106 MT, TCT or BT suspensions
in 0.2 ml PBS via i.p., i.v. or s.c. injection. For drug treatments,
benznidazole was prepared from powder at 10 mg ml−1 in
7% Tween-80, 3% ethanol (vol/vol). Mice were treated with
100 mg kg−1 day−1 for 5 consecutive days by oral gavage. At
experimental end-points mice were sacrificed by ex-sanguination
under terminal anaesthesia.
Bioluminescence imaging
Mice were injected with 150 mg kg−1 d-luciferin i.p., then anaes-
thetized using 2.5% (vol/vol) gaseous isofluorane in oxygen. To
measure bioluminescence, mice were placed in an IVIS Lumina
II system (Caliper Life Science) and images were acquired 10–20
min after d-luciferin administration using LivingImage 4.3. Expo-
sure times varied between 1 s and 5 min, depending on signal
intensity. After imaging, mice were revived and returned to cages.
For ex vivo imaging, mice were injected with 150 mg kg−1
d-luciferin i.p., then sacrificed by ex-sanguination under ter-
minal anaesthesia 7 min later. Mice were perfused with 10 ml
0.3 mg ml−1 d-luciferin in PBS via the heart. Organs and tissues
were excised, transferred to a Petri dish or culture dish, soaked
in 0.3 mg ml−1 d-luciferin in PBS, and then imaged as per live
mice. To estimate parasite burden in live mice, regions of interest
(ROIs) were drawn using LivingImage v.4.3 to quantify biolumi-
nescence expressed as total flux (photons/second). The detec-
tion threshold for in vivo imaging was estimated using whole
animal ROI data (n = 25) for control uninfected mice obtained on
11 different days. To estimate parasite load in ex vivo tissues,
individual ROIs were drawn to quantify bioluminescence
expressed as radiance (photons second−1 cm−2 sr−1). Because
different tissue types from uninfected control mice were found to
have slightly different background radiances, we normalized the
data from infected mice using matching tissues from uninfected
controls and used the fold-change in radiance compared to these
tissue-specific controls as the final measure of ex vivo biolumi-
nescence. The detection threshold for ex vivo imaging was esti-
mated using the fold-change in radiance for empty ROIs in
images obtained for infected mice compared with matching
empty ROIs in images for uninfected control mice.
Histology
Tissue samples were fixed in 10% buffered formalin for 48–72 h,
dehydrated, cleared, and embedded in paraffin. Sections (5 μm)
were stained with haematoxylin and eosin or with Masson’s
trichrome. Histomorphometric studies of inflammation involved
analysis of 20 images from randomly selected fields of tissue
sections on a single slide per animal. An index of inflammatory
infiltration was derived by quantifying the total number of nuclei
present in each image (Caliari, 1997). A fibrosis index was
derived by quantifying the collagen content of each sample using
30 randomly selected fields for each section stained by Masson’s
trichrome technique. Blue pixels were counted for the creation of
a binary image and posterior calculus of the total area occupied
with fibrosis (Caliari et al., 2002). All images were taken with a
DFC420 light microscope (Leica Microsystems) and analysed
using Leica Application Suite software v.4.2 by an investigator
blinded to the groups.
qPCR
Organs and tissues were snap frozen on dry ice and stored at
−80°C. For DNA extraction, samples were thawed and immedi-
ately homogenized in at least 200 μl lysis buffer (4 M urea,
200 mM Tris, 20 mM NaCl, 200 mM EDTA, pH 7.4) per 50 mg
tissue using a BulletBlender Storm instrument (Next Advance).
The tissue suspension was then incubated overnight at 37°C with
0.6 mg proteinase K. DNAwas extracted using the High Pure PCR
product purification kit (Roche). Real-time PCR reactions were
prepared using the QuantiTect SYBR Green PCR Kit (Qiagen) and
run on a RotorGene 3000 instrument. Each reaction contained
50 ng DNA and 0.5 μM of each primer. T. cruzi-specific primers
TCZ-F and TCZ-R (Cummings and Tarleton, 2003), targeted at the
195 bp satellite repeat, and mouse-specific primers GAPDHf and
GAPDHr (Cencig et al., 2011), targeted at the murine gapdh gene,
were used. Measurements of T. cruzi DNA content were normal-
ized using the ratio of Ct values for T. cruzi- and mouse-specific
PCRs, and converted to estimated numbers of parasite equiva-
lents by reference to a standard curve with a range of 2.5 × 106–
2.5 × 10−1 parasite equivalents ml−1. The standard curve was
established from serial dilution of a DNA sample derived from
75 mg homogenized muscle tissue, spiked with 2 × 107 epima-
stigotes, using DNA from unspiked equivalent samples as the
diluent.
Statistics
Individual animals were used as the unit of analysis of in vivo and
ex vivo experiments. No blinding or randomization protocols were
used. Sample sizes were determined empirically. Statistical dif-
ferences between groups were evaluated using one-way ANOVA
with Bonferroni post-hoc correction for normally distributed data
or using a Kruskal–Wallis test with Dunn’s post-hoc correction for
non-normally distributed data, both in GraphPad Prism v.6. Data
sets were tested for departure from normal distribution using the
Shapiro-Wilk test in SPSS v.20. Differences of P < 0.05 were
considered significant.
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version of this article at the publisher’s web-site:
Fig. S1. Confirmation of genomic integration of the PpyRE9h
reporter gene. Schematic illustrating integration of linearized
pTRIX2-RE9h into the T. cruzi genome by homologous recombi-
nation. Integration was confirmed by Southern blot of BamHI (B)
and XhoI (X) digested genomic DNA from G418-resistant clones
with a radiolabelled PpyRE9h ssDNA probe as indicated. The
autoradiograph shows data for wild-type (WT) parasites and five
transgenic clones (1–5). The probe localized to the expected
8.6 kb BamHI band in all five clones and a variably sized XhoI
band indicating integration into different rDNA repeats. Clone 3
was used for all further experiments.
Fig. S2. Tissue-specific parasite distributions and loads in
acutely infected SCID mice.
A. Examples of heart, skeletal muscle and colon samples from
SCID mice with fulminant infections showing presence of intrac-
ellular amastigotes (arrows). Histological sections were stained
with Masson’s trichrome (heart) or haematoxylin and eosin
(skeletal muscle, colon). Heart and colon: 1000× magnification,
scale bar = 30 μm; skeletal muscle: 400× magnification, scale
bar = 50 μm.
B and C. Quantification of ex vivo bioluminescence for selected
organs and tissues taken immediately post-mortem from SCID
mice 17 days after infection with 1 × 103 PpyRE9h luciferase-
expressing T. cruzi trypomastigotes.
B. Images of selected organs and tissues from representative
uninfected control and infected SCID mice overlaid with
bioluminescence heat-map. Both images use the same log10
pseudocolour scale to indicate intensity of bioluminescence from
low (blue) to high (red); the minimum and maximum radiances
are indicated. Red lines demarcate regions of interest used to
quantify tissue-specific bioluminescence. B, brain; C, colon; H,
heart; K, kidney; Li, liver; Lu, lung; Me, gut mesenteries; Mu,
skeletal muscle; O, ovary; R, ribcage; SF, subcutaneous fat; Sp,
spleen; St, stomach; U, uterus; VF, visceral fat.
C. Quantification of tissue- and organ-specific bioluminescence
for SCID mice inoculated by i.p and i.v. routes (n = 3 per group).
Data are means + SD of the fold-change in bioluminescence
intensity for organs from infected mice compared with matching
organs from uninfected mice.
Fig. S3. Daily quantitative fluctuation and spatial dynamism of
chronic T. cruzi infections in BALB/c mice. Ventral and dorsal
images of the same three individual BALB/c mice chronically
infected with PpyRE9h luciferase-expressing T. cruzi over the
course of 10 days. All images use the same log10 scale heat-
map with minimum and maximum radiance values as indicated.
Representative of three mice per experiment.
Fig. S4. Tissue-specific parasite distributions and loads in
acutely infected BALB/c mice. Quantification of ex vivo biolumi-
nescence for selected organs and tissues taken immediately
post-mortem from BALB/c mice infected with PpyRE9h
luciferase-expressing T. cruzi. Animals were inoculated by i.p.
injection of 1 × 103 trypomastigotes and ex vivo imaging was
performed at 14 dpi (n = 8, except lung n = 7 and peritoneum
n = 6) and 35 dpi (n = 9 for all tissues). Data are means + SD of
the fold-change in bioluminescence intensity for organs from
infected mice compared with matching organs from uninfected
mice and are pooled from two independent experiments (n ≥ 3
mice per time point per experiment). Dashed line indicates the
detection threshold equal to the mean +2SDs of the fold-change
in bioluminescence intensity for empty regions of interest (ROI) in
the images obtained for infected mice compared with empty ROI
in the images obtained for uninfected mice.
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